Telogen Effluvium: A Comprehensive Review

    August 2019 in “ DOAJ (DOAJ: Directory of Open Access Journals) ”
    Alfredo Rebora
    Image of study
    TLDR Telogen effluvium is a common, distressing condition causing excessive hair shedding and has significant psychological effects on patients.
    The document "Telogen effluvium: a comprehensive review" from 2019 discussed the common and distressing condition of excessive hair shedding, known as telogen effluvium (TE). The author, Alfredo Rebora, highlighted several issues related to TE, including the difficulty in determining how severe hair loss must be for a TE diagnosis, the need for proper classification due to its heterogeneity, and its distinction from androgenetic alopecia (AGA), which it is often associated with. The paper also discussed trichodynia, a main symptom of TE, the nonspecific nature of its histopathology, and its management from diagnosis to treatment. The author emphasized that dermatologists should not minimize the complaint as TE can have a significant psychological impact on patients.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 404 results

      community AGA evaluation and first steps - BEGINNER MEGAPOST

      in Chat  73 upvotes 2 months ago
      The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.

      community FINASTRIDE and switch to DUTASTRIDE, my experience

      in Progress Pictures  135 upvotes 2 months ago
      The user shared their experience with Finasteride and Dutasteride for hair loss. They initially had success with Finasteride but switched to Dutasteride after experiencing shedding, which continued, and are now considering a hair transplant.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  40 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

      community C’est terrible - at my wits end

      in Female  443 upvotes 1 year ago
      A 29-year-old woman is experiencing gradual hair thinning since age 15, suspects Androgenic Alopecia, and has tried 5% minoxidil with little success. She has purchased various hair loss treatments including minoxidil, dutasteride, finasteride, and spironolactone, but is cautious about starting them due to potential interactions with her ADHD medication.

    Similar Research

    6 / 1000+ results